Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294563 | 0.89 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29914599 | 0.89 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16891300 | 0.88 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL69358 | 0.85 | LIPG (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29506426 | 0.85 | LIPG (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL18723376 | 0.85 | LIPG (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12681698 | 0.85 | LIPG (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16868738 | 0.82 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16435209 | 0.82 | LIPG (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL23568130 | 0.81 | LPL (0.46) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512108-B2 | 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-12-06 | — | — | US | disclosed |
| US-9512108-B2 | 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-12-06 | — | — | US | disclosed |
| US-9512108-B2 | 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-12-06 | — | — | US | disclosed |
| EP-3091010-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| EP-3091010-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-10-13 | — | — | US | disclosed |
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-10-13 | — | — | US | disclosed |
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-10-13 | — | — | US | disclosed |
| WO-2015101215-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | 南京圣和药业股份有限公司 | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | SLC10A1, CYP2C9, UGT1A9 | LPL 1667/4885LIPG 2600/4885CA1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.